Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amylin’s SymlinPen To Launch In December

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm gets mixed blessing from FDA as agency says combination of pramlintide and basal insulin is "not approvable."
Advertisement

Related Content

Amylin CEO: Firm Can Do Better With Byetta
Amylin CEO: Firm Can Do Better With Byetta
Amylin Obesity Combo Scores Big Weight Loss In Phase IIa Trial
Amylin Obesity Combo Scores Big Weight Loss In Phase IIa Trial
Exenatide LAR Phase III Non-Inferiority Data Anticipated In Q4, Amylin Says
FDA Internal Review To Evaluate Potential Symlin Dosing Confusion
FDA Internal Review To Evaluate Potential Symlin Dosing Confusion
Amylin’s Symlin Diabetes Therapy Gets FDA Nod

Topics

Advertisement
UsernamePublicRestriction

Register

PS065156

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel